Korecyte Bio develops next-generation cellular immunotherapies designed to safely target solid cancers. The company utilizes its proprietary HypoxiCAR platform to genetically engineer immune cells that remain dormant until activated within a tumor microenvironment. This approach aims to provide safer and more effective CAR-T immunotherapy outcomes for patients with solid tumors.
Funding
Funding not disclosed
Founders
Product
Problem
Traditional CAR-T therapies often exhibit systemic toxicity due to their continuous activation and off-target effects, limiting the dosage and efficacy against solid tumors. The inability to specifically target tumor microenvironments leads to significant side effects and compromised patient outcomes.
Solution
Korecyte Bio is developing the HypoxiCAR platform, a modular technology designed to enhance the safety and efficacy of CAR-T cell therapies for solid tumors. This platform genetically engineers T-cells to remain inactive until they encounter the hypoxic conditions characteristic of solid tumor microenvironments. Upon detecting these conditions, the HypoxiCAR-modified T-cells selectively activate, targeting and destroying cancer cells while minimizing damage to healthy tissues. This targeted approach aims to improve patient outcomes by reducing systemic toxicity and enabling higher doses of CAR-T cells to be administered. The HypoxiCAR technology preserves the killing potential of CAR-T cells, allowing for a more effective and safer treatment option for patients with solid tumors.
Target Audience
The primary target audience includes cancer patients with solid tumors, as well as clinicians and researchers in the field of oncology and cell therapy.
Features
- Modular HypoxiCAR platform adaptable to various CAR-T cell constructs
- Genetically engineered T-cells that remain dormant until sensing hypoxic tumor microenvironments
- Selective activation within solid tumors to minimize off-target effects
- Enhanced CAR-T cell persistence and killing potential within the tumor
- Reduced systemic toxicity compared to traditional CAR-T therapies
- Potential for higher CAR-T cell dosage to improve efficacy